Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2024, Vol. 29 ›› Issue (3): 334-338.doi: 10.12092/j.issn.1009-2501.2024.03.012

Previous Articles     Next Articles

Safety of G-CSF in patients with COVID-19

LIU Heng1, LI Zijian2   

  1. 1 The First Clinical Medical College of Lanzhou University; 2 Department of Hematology, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu, China
  • Received:2023-08-04 Revised:2023-10-24 Online:2024-03-26 Published:2024-02-29

Abstract:

COVID-19, a disease caused by SARS-CoV-2 infection, has caused a global pandemic in a short time. The key immunopathological features of COVID-19 include lymphopenia, neutropenia, cytokine storm and related Immune damage to parenchymal organs such as lung. Granulocyte colony stimulating factor (G-CSF) can cause excessive inflammatory reaction, which may aggravate the condition of some patients. Therefore, it is controversial whether COVID-19 should be treated with G-CSF, and clinicians need to evaluate the effectiveness and safety of G-CSF according to the specific conditions of each patient.

Key words: COVID-19, SARS-CoV-2, G-CSF, benefit, risk

CLC Number: